Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Pasireotide

Last Updated: 03/28/17

Status: Determined Ineffective for NF2

Index

  1. Basic Information
  2. Trials
  3. Side Effects

Other Names SOM230, SOM 230, UNII-98H1T17066
Prescription Information SOM230
Trade Name Orphan Drug
Pharmaceutical Company Novartis
Treatment By IV
Effect Expectation Brain Meningiomas
Pipeline Data Novartis
Inhibitor Small Somatostatin (SST)
SST is a Growth Hormone (GH) Inhibited
Molecular Formula C58H66N10O9
IUPAC Name [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate

1. Basic Information

Treatment with Pasireotide, also known as SOM230, is meant to shrink brain Meningiomas tumor mass.

Many tumor suppressors for NF2 effect primarily brain Schwannoma tumors that are doing damage to different Cranial Nerves. However Meningiomas are issues as well.

Schwannoma tumors damage the nerves they grown on which is dangerous, but as Meningiomas grow larger, they are just as dangerous as they cause pressure on brain matter and result in different brain function issues. Issues developed would be based on the exact location and possibly size of each problematic tumor.

2. Trials


3. Side Effects

  • Blood Pressure
  • Cholesterol Value
  • Weight Loss
  • Diarrhea
  • Abdominal Discomfort
  • Nausea
  • Vomiting